1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

GSK Consumer Leaving Costa Rica: Consumer Health News Roundup

GSK closing Costa Rica consumer product plant; PPI study authors suggest physicians’ counsel on OTC use; and Makesense topicals recall.

GlaxoSmithKline PLC plans over a three-year period to move its Costa Rica manufacturing operation to production capacity available in other sites of its network in Latin America while keeping its Pharmaceutical and Consumer Healthcare divisions and its Business Services Center in the country. The UK pharma firm on Feb. 23 said it will transfer production and packaging of Eno antacid effervescent sachets and Panadol (paracetamol [acetaminophen]) liquid products to other sites. Glaxo, which markets its and Novartis AG’s consumer health care products in a joint venture, GSK Consumer Healthcare LP, said it will transfer the product lines manufactured in San Jose, Costa Rica, in a process that will begin this year and end in 2019, closing a site that has been producing and supplying multiple products for more than 60 years. Manufacturing will continue at the site until all product lines are transferred to other GSK sites in multiple phases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Plans Clinical Data Protection By Product Category For First Time

 
• By Xu Hu

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By Xu Hu

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 
• By Dexter Jie Yan

While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.

China Signals Commercial Insurance, Biotech And Foreign-Owned Hospitals As Policy Priorities

 
• By Xu Hu

The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.